Anti-TNF withdrawal in inflammatory bowel disease

Joana Torres; Marília Cravo; Jean Frédéric Colombel

doi:10.1016/j.jpge.2015.11.004

Anti-TNF withdrawal in inflammatory bowel disease

Joana Torres^*, Marília Cravo, Jean Frédéric Colombel

^*Corresponding author for this work

Research output: Contribution to journal › Short survey › peer-review

8 Citations (Scopus)

Abstract

The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF withdrawal has emerged as an important consideration in clinical practice. Herein our goal was to discuss the available evidence about anti-TNFα discontinuation in IBD that could inform the clinician on the expected rates of relapse, the potential predictors of relapse, as well the response to re-treatment.

Translated title of the contribution	Discontinuação dos Anti-TNF na doença inflamatória intestinal
Original language	English
Pages (from-to)	153-161
Number of pages	9
Journal	GE Portuguese Journal of Gastroenterology
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/j.jpge.2015.11.004
Publication status	Published - 1 May 2016
Externally published	Yes

Keywords

Inflammatory Bowel Diseases/drug therapy
Tumor Necrosis Factor-Alpha/antagonists and inhibitors
Tumor Necrosis Factor-Alpha/therapeutic use
Withholding treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jpge.2015.11.004Licence: CC BY-NC-ND

Cite this

@article{2c9acc2a9baf49a2b6fa7f462c127b58,

title = "Anti-TNF withdrawal in inflammatory bowel disease",

abstract = "The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF withdrawal has emerged as an important consideration in clinical practice. Herein our goal was to discuss the available evidence about anti-TNFα discontinuation in IBD that could inform the clinician on the expected rates of relapse, the potential predictors of relapse, as well the response to re-treatment.",

keywords = "Inflammatory Bowel Diseases/drug therapy, Tumor Necrosis Factor-Alpha/antagonists and inhibitors, Tumor Necrosis Factor-Alpha/therapeutic use, Withholding treatment, Doen{\c c}a Inflamat{\'o}ria Intestinal/tratamento, Inibidores Factor de Necrose Tumoral Alfa/antagonistas & inibidores, Factor de Necrose Tumoral Alfa/uso terap{\^e}utico, Suspens{\~a}o de tratamento",

author = "Joana Torres and Mar{\'i}lia Cravo and Colombel, {Jean Fr{\'e}d{\'e}ric}",

note = "Publisher Copyright: {\textcopyright} 2015 Sociedade Portuguesa de Gastrenterologia.",

year = "2016",

month = may,

day = "1",

doi = "10.1016/j.jpge.2015.11.004",

language = "English",

volume = "23",

pages = "153--161",

journal = "GE Portuguese Journal of Gastroenterology",

issn = "2341-4545",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Anti-TNF withdrawal in inflammatory bowel disease

AU - Torres, Joana

AU - Cravo, Marília

AU - Colombel, Jean Frédéric

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF withdrawal has emerged as an important consideration in clinical practice. Herein our goal was to discuss the available evidence about anti-TNFα discontinuation in IBD that could inform the clinician on the expected rates of relapse, the potential predictors of relapse, as well the response to re-treatment.

AB - The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF withdrawal has emerged as an important consideration in clinical practice. Herein our goal was to discuss the available evidence about anti-TNFα discontinuation in IBD that could inform the clinician on the expected rates of relapse, the potential predictors of relapse, as well the response to re-treatment.

KW - Inflammatory Bowel Diseases/drug therapy

KW - Tumor Necrosis Factor-Alpha/antagonists and inhibitors

KW - Tumor Necrosis Factor-Alpha/therapeutic use

KW - Withholding treatment

KW - Doença Inflamatória Intestinal/tratamento

KW - Inibidores Factor de Necrose Tumoral Alfa/antagonistas & inibidores

KW - Factor de Necrose Tumoral Alfa/uso terapêutico

KW - Suspensão de tratamento

UR - http://www.scopus.com/inward/record.url?scp=85006197292&partnerID=8YFLogxK

U2 - 10.1016/j.jpge.2015.11.004

DO - 10.1016/j.jpge.2015.11.004

M3 - Short survey

C2 - 28868451

AN - SCOPUS:85006197292

SN - 2341-4545

VL - 23

SP - 153

EP - 161

JO - GE Portuguese Journal of Gastroenterology

JF - GE Portuguese Journal of Gastroenterology

IS - 3

ER -

Anti-TNF withdrawal in inflammatory bowel disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this